Your browser doesn't support javascript.
loading
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar, Arjun V; Galsky, Matthew D; Rosenberg, Jonathan E; Powles, Thomas; Petrylak, Daniel P; Bellmunt, Joaquim; Loriot, Yohann; Necchi, Andrea; Hoffman-Censits, Jean; Perez-Gracia, Jose Luis; Dawson, Nancy A; van der Heijden, Michiel S; Dreicer, Robert; Srinivas, Sandy; Retz, Margitta M; Joseph, Richard W; Drakaki, Alexandra; Vaishampayan, Ulka N; Sridhar, Srikala S; Quinn, David I; Durán, Ignacio; Shaffer, David R; Eigl, Bernhard J; Grivas, Petros D; Yu, Evan Y; Li, Shi; Kadel, Edward E; Boyd, Zachary; Bourgon, Richard; Hegde, Priti S; Mariathasan, Sanjeev; Thåström, AnnChristine; Abidoye, Oyewale O; Fine, Gregg D; Bajorin, Dean F.
Afiliación
  • Balar AV; Genitourinary Cancers Program, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA. Electronic address: arjun.balar@nyumc.org.
  • Galsky MD; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Rosenberg JE; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Powles T; Barts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London, London, UK.
  • Petrylak DP; Smilow Cancer Center, Yale University, New Haven, CT, USA.
  • Bellmunt J; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Loriot Y; Département de médecine oncologique, Université Paris-Saclay and Gustave Roussy, Villejuif, France.
  • Necchi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Hoffman-Censits J; Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.
  • Perez-Gracia JL; Department of Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Navarre, Spain.
  • Dawson NA; Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • van der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Dreicer R; Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Srinivas S; Division of Oncology/Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Retz MM; Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Joseph RW; Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.
  • Drakaki A; Department of Medicine, Division of Hematology and Oncology and Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Vaishampayan UN; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Sridhar SS; Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, ON, Canada.
  • Quinn DI; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Durán I; Department of Medical Oncology, Hospital Universitario Virgen del Rocío and Institute of Biomedicine of Seville, Seville, Spain.
  • Shaffer DR; New York Oncology Hematology, Albany, NY, USA.
  • Eigl BJ; British Columbia Cancer Agency, British Columbia, Vancouver, Canada.
  • Grivas PD; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Yu EY; Division of Oncology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Li S; Genentech, South San Francisco, CA, USA.
  • Kadel EE; Genentech, South San Francisco, CA, USA.
  • Boyd Z; Genentech, South San Francisco, CA, USA.
  • Bourgon R; Genentech, South San Francisco, CA, USA.
  • Hegde PS; Genentech, South San Francisco, CA, USA.
  • Mariathasan S; Genentech, South San Francisco, CA, USA.
  • Thåström A; Genentech, South San Francisco, CA, USA.
  • Abidoye OO; Genentech, South San Francisco, CA, USA.
  • Fine GD; Genentech, South San Francisco, CA, USA.
  • Bajorin DF; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lancet ; 389(10064): 67-76, 2017 01 07.
Article en En | MEDLINE | ID: mdl-27939400
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Transicionales / Neoplasias Urológicas / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Transicionales / Neoplasias Urológicas / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido